SG Americas Securities
KROS icon

SG Americas Securities’s Keros Therapeutics KROS Stock Holding History

SG Americas Securities’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,135
Closed -$101K – 3529
2026
Q1 		$101K Sell
9,135
-89,568
-91% -$1.38M ﹤0.01% 2933
2025
Q4 		$2.01M Buy
98,703
+92,212
+1,421% +$1.62M ﹤0.01% 1533
2025
Q3 		$103K Buy
+6,491
New +$95.9K ﹤0.01% 3071
2025
Q1 		– Sell
-24,493
Closed -$388K – 3612
2024
Q4 		$388K Buy
+24,493
New +$1.27M ﹤0.01% 1573
2024
Q3 		– Sell
-11,633
Closed -$532K – 3518
2024
Q2 		$532K Buy
+11,633
New +$625K ﹤0.01% 1649
2024
Q1 		– Sell
-12,252
Closed -$487K – 3211
2023
Q4 		$487K Sell
12,252
-34,931
-74% -$1.1M ﹤0.01% 1502
2023
Q3 		$1.5M Buy
47,183
+38,857
+467% +$1.45M 0.02% 937
2023
Q2 		$335K Sell
8,326
-19,728
-70% -$865K ﹤0.01% 1566
2023
Q1 		$1.2M Buy
28,054
+13,949
+99% +$705K 0.01% 1020
2022
Q4 		$677K Buy
14,105
+6,079
+76% +$284K 0.01% 1276
2022
Q3 		$302K Sell
8,026
-4,771
-37% -$165K ﹤0.01% 1988
2022
Q2 		$354K Buy
12,797
+9,853
+335% +$432K ﹤0.01% 2258
2022
Q1 		$160K Buy
2,944
+243
+9% +$12.5K ﹤0.01% 2543
2021
Q4 		$158K Sell
2,701
-4,582
-63% -$228K ﹤0.01% 2792
2021
Q3 		$288K Buy
+7,283
New +$259K ﹤0.01% 2978
2021
Q2 		– Sell
-2,725
Closed -$168K – 3058
2021
Q1 		$168K Buy
+2,725
New +$173K ﹤0.01% 2790
2020
Q3 		– Sell
-4,087
Closed -$153K – 3091
2020
Q2 		$153K Buy
+4,087
New +$126K ﹤0.01% 3084

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

SG Americas Securities's KROS Position: Q2 2026 in Review

SG Americas Securities sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 9,135 shares — an estimated $101K sold.

SG Americas Securities first reported a position in KROS in Q2 2020 and held it in 17 quarters. The position peaked at $2.01M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • SG Americas Securities reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 9,135 Keros Therapeutics shares in Q2 2026, an estimated $101K.
  • SG Americas Securities first reported a position in Keros Therapeutics in Q2 2020 and held it in 17 quarters.
  • SG Americas Securities's Keros Therapeutics position peaked at $2.01M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.